MDS Inc. and Danaher Corporation Receive Second Request for Information from U.S. Federal Trade Commission for MDS Analytical Te
03 November 2009 - 1:00PM
PR Newswire (US)
TORONTO, and WASHINGTON, D.C., Nov. 3 /PRNewswire-FirstCall/ -- MDS
Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and
services to the global life sciences markets, and Danaher
Corporation (NYSE:DHR), a diversified technology leader, today
announced that they have each received a Second Request for
information from the Federal Trade Commission (FTC) regarding the
sale of MDS Analytical Technologies. The Second Request relates to
a global market segment that MDS and Danaher estimate generates
less than $50 million in annual revenues for all sellers combined.
The information request was issued under notification requirements
of the Hart Scott Rodino Antitrust Improvements Act of 1976, as
amended (HSR Act). The effect of the Second Request is to extend
the waiting period imposed by the HSR Act for a period of 30
calendar days from the date of the parties' substantial compliance
with the request, unless the waiting period is earlier terminated.
MDS Inc. and Danaher Corporation continue to cooperate with the FTC
and currently expect the transaction, which was announced on
September 2, 2009 and received approval from MDS shareholders on
October 20, 2009, to close before the end of the first calendar
quarter of 2010, subject to the satisfaction of the conditions to
closing. About Danaher Corporation Danaher is a diversified
technology leader that designs, manufactures, and markets
innovative products and services to professional, medical,
industrial, and commercial customers. Our portfolio of premier
brands is among the most highly recognized in each of the markets
we serve. Driven by a foundation provided by the Danaher Business
System, our 50,000 associates serve customers in more than 125
countries and generated $12.7 billion of revenue in 2008. For more
information, please visit our Website: http://www.danaher.com/
About MDS Inc. MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life
sciences company that provides market-leading products and services
that customers need for the development of drugs and diagnosis and
treatment of disease. MDS Inc. is a leading global provider of
pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS has
more than 3,600 highly skilled people in 13 countries. Find out
more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day. DATASOURCE: MDS Inc. CONTACT: MDS CONTACTS: MEDIA:
Janet Ko, (905) 267-4226, ; INVESTORS: Peter Dans, (905) 267-4230,
; DANAHER CONTACT: MEDIA AND INVESTORS: Matt McGrew, (202)
828-0850,
Copyright